Efficacy of tyrosine kinase inhibitors in nonsmallcell lung cancer patients undergoing dose reduction and those with a low body surface area

Author：                    

Publisher： Spandidos Publications

ISSN： 2049-9469

Source： Molecular and Clinical Oncology, Vol.2, Iss.4, 2014-01, pp. : 604-608

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in nonsmallcell lung cancer and sensitivity to AZD7451 in vitro

By                    

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 725-730

Spandidos Publications

Access to resources Recommend Favorite

Misjudgement of gefitinib efficacy in patients with central non-smallcell lung cancer due to obstructive atelectasis caused by stereotactic radiotherapy

By                

Molecular and Clinical Oncology, Vol. 2, Iss. 4, 2014-01 ,pp. : 535-538

Spandidos Publications

Access to resources Recommend Favorite

Efficacy of chemotherapy plus gefitinib treatment in advanced nonsmallcell lung cancer patients following acquired resistance to gefitinib

By    

Molecular and Clinical Oncology, Vol. 1, Iss. 5, 2013-01 ,pp. : 875-878

Spandidos Publications

Access to resources Recommend Favorite

Cyclooxygenase2 inhibitors for nonsmallcell lung cancer: A phase II trial and literature review

By                        

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 744-750

Spandidos Publications

Access to resources Recommend Favorite

The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from nonsmallcell lung cancer

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 116-120

Spandidos Publications

Access to resources Recommend Favorite